Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

GBM cell

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (1) Akt (2) Antibiotic (1) Apoptosis (21) Aurora Kinase (1) Autophagy (2) Bcl-2 Family (3) c-Myc (2) Caspase (9) CDK (1) Checkpoint Kinase (Chk) (1) Cytochrome P450 (1) DNA Alkylator/Crosslinker (1) DNA Methyltransferase (1) DNA-PK (1) DNA/RNA Synthesis (1) Dopamine Receptor (1) Drug Derivative (3) DYRK (4) EGFR (7) Emopamil Binding Protein (1) Epigenetic Reader Domain (2) ERK (1) Estrogen Receptor/ERR (1) FAK (2) Ferroptosis (1) FGFR (1) Glycosidase (1) GSK-3 (1) HDAC (1) Hedgehog (1) Histone Demethylase (1) Histone Methyltransferase (1) HSP (3) IAP (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Interleukin Related (1) LIM Kinase (LIMK) (1) LPL Receptor (1) LXR (1) MDM-2/p53 (1) Microtubule/Tubulin (7) MMP (1) Monoamine Oxidase (2) mTOR (4) Necroptosis (1) NF-κB (5) P2X Receptor (1) p38 MAPK (1) Parasite (2) PKA (1) PROTACs (1) Pyk2 (1) Ras (1) Reactive Oxygen Species (ROS) (2) Reference Standards (3) RIP kinase (2) SDCBP (1) SGK (1) Src (1) STAT (1) Survivin (2) SWI/SNF Complex (1) TNF Receptor (1) Trk Receptor (1) VEGFR (1) WDR5 (1)
By Research Areas:	Cancer (64) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (4) Metabolic Disease (1) Neurological Disease (17)

By Targets:

ADC Payload (1)

Akt (2)

Antibiotic (1)

Apoptosis (21)

Aurora Kinase (1)

Autophagy (2)

Bcl-2 Family (3)

c-Myc (2)

Caspase (9)

CDK (1)

Checkpoint Kinase (Chk) (1)

Cytochrome P450 (1)

DNA Alkylator/Crosslinker (1)

DNA Methyltransferase (1)

DNA-PK (1)

DNA/RNA Synthesis (1)

Dopamine Receptor (1)

Drug Derivative (3)

DYRK (4)

EGFR (7)

Emopamil Binding Protein (1)

Epigenetic Reader Domain (2)

ERK (1)

Estrogen Receptor/ERR (1)

FAK (2)

Ferroptosis (1)

FGFR (1)

Glycosidase (1)

GSK-3 (1)

HDAC (1)

Hedgehog (1)

Histone Demethylase (1)

Histone Methyltransferase (1)

HSP (3)

IAP (1)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Interleukin Related (1)

LIM Kinase (LIMK) (1)

LPL Receptor (1)

LXR (1)

MDM-2/p53 (1)

Microtubule/Tubulin (7)

MMP (1)

Monoamine Oxidase (2)

mTOR (4)

Necroptosis (1)

NF-κB (5)

P2X Receptor (1)

p38 MAPK (1)

Parasite (2)

PKA (1)

PROTACs (1)

Pyk2 (1)

Ras (1)

Reactive Oxygen Species (ROS) (2)

Reference Standards (3)

RIP kinase (2)

SDCBP (1)

SGK (1)

Src (1)

STAT (1)

Survivin (2)

SWI/SNF Complex (1)

TNF Receptor (1)

Trk Receptor (1)

VEGFR (1)

WDR5 (1)

By Research Areas:

Cancer (64)

Cardiovascular Disease (1)

Infection (3)

Inflammation/Immunology (4)

Metabolic Disease (1)

Neurological Disease (17)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Programmed Cell Death 4 (PDCD4) Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor BCL6 Tim3 VISTA BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17595

Mebendazole Maximum Cited Publications 8 Publications Verification	Parasite Apoptosis Microtubule/Tubulin	Infection Cancer
Mebendazole is a highly effective, broad-spectrum antihelmintic against nematode infestations. Mebendazole also exhibits inhibitory effect against glioblastoma multiforme (GBM), inhibits Hedgehog pathway and tubulin polymerization. Mebendazole is orally active and can cross CNS penetration .

HY-12456

Duocarmycin SA	Antibiotic ADC Payload DNA Alkylator/Crosslinker Necroptosis Apoptosis	Cancer
Duocarmycin SA is an orally active antitumor antibiotic with an IC₅₀ of 10 pM . Duocarmycin SA is an extremely potent cytotoxic agent capable of inducing a sequence-selective alkylation of duplex DNA. Duocarmycin SA demonstrates synergistic cytotoxicity against glioblastoma multiforme (GBM) cells treated with proton radiation in vitro .

HY-108476

INDY 2 Publications Verification	DYRK	Cancer
INDY is a potent and ATP-competitive Dyrk1A and Dyrk1B inhibitor with IC₅₀s of 0.24 μM and 0.23 μM, respectively. INDY binds in the ATP pocket of the enzyme and has a K_i value of 0.18 μM for Dyrk1A. INDY sharply reduces the self-renewal capacity of normal and tumorigenic cells in primary Glioblastoma (GBM) cell lines and neural progenitor cells .

HY-122815

Fusicoccin Fusicoccin A	Apoptosis	Cancer
Fusicoccin (Fusicoccin A), a fungal pytotoxin, is a stabilizer of specific 14-3-3 protein-protein interactions. Fusicoccin sabilizes H ⁺-ATPase/14-3-3 cmplex in pants, maintaining the enzyme in activated state. Fusicoccin also stabilizes 14-3-3 protein interactions with binding partners containing a C-terminal 14-3-3 recognition motif (a mode 3 motif), such as ERα, GPIbα, TASK3, CTFR, and p53. Fusicoccin induces apoptosis in cancer cells and has anticancer activity .

HY-19939S

VX-984 4 Publications Verification M9831	DNA-PK	Cancer
VX-984 is an orally active, potent, selective and BBB-penetrated DNA-PK inhibitor. VX-984 efficiently inhibits NHEJ (non-homologous end joining) and increases DSBs (DNA double-strand breaks). VX-984 can be used for glioblastomas (GBM) and non-small cell lung cancer (NSCLC) research. VX-984 is a de novo deuterium .

HY-13610A

N1,N11-Diethylnorspermine tetrahydrochloride 4 Publications Verification Diethylnorspermine tetrahydrochloride; DENSPM tetrahydrochloride; BENSPM tetrahydrochloride	Caspase mTOR	Cancer
N1, N11-Diethylnorspermine tetrahydrochloride (DENSPM tetrahydrochloride) is a potent anticancer agent. N1,N11-Diethylnorspermine tetrahydrochloride activates polyamine catabolism and downregulates mTOR protein. N1,N11-Diethylnorspermine tetrahydrochloride induces the release of cytochrome c from mitochondria, resulting in activation of caspase 3. N1,N11-Diethylnorspermine tetrahydrochloride kills glioblastoma multiforme (GBM) through induction of SSAT (spermidine/spermine N1-acetyltransferase) coupled with H₂O₂ production .

HY-14942A

Berubicin hydrochloride RTA 744; WP 744; WP 769 hydrochloride	NF-κB Apoptosis Caspase Drug Derivative	Neurological Disease Cancer
Berubicin (RTA 744) hydrochloride is a Doxorubicin (HY-15142A) analog that can cross the blood-brain barrier. Berubicin hydrochloride inhibits P-gp and MRP1-mediated efflux and suppresses glioblastoma multiforme (GBM). Berubicin hydrochloride exerts toxic effects on leukemia cells by activating nuclear factor κB (NF-κB) and induces apoptosis in neuroblastoma cells. Berubicin hydrochloride can be used in the study of tumors related to the nervous system .

HY-153268

Silevertinib 2 Publications Verification BDTX-1535; EGFR-IN-76	EGFR	Infection Neurological Disease Metabolic Disease Cancer
Silevertinib (BDTX-1535) is an irreversible, brain-penetrant, selective and orally active EGFR inhibitor with wild-type EGFR-sparing. Silevertinib targets key EGFR resistance mutations, including the kinase domain (C797S, L718Q, G724S, S768I), extracellular domain (EGFRvIII, A289X), and EGFR amplification. Silevertinib exerts anti-tumor activity with well tolerated in vivo. Silevertinib can be used for non-small cell lung cancer (NSCLC) and glioblastoma (GBM) research .

HY-P99139

Anti-Mouse IL-1b Antibody (B122)	Interleukin Related Reactive Oxygen Species (ROS) Ferroptosis	Cardiovascular Disease Inflammation/Immunology Cancer
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonal antibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combined with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for researches on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure .

HY-P99445

Asunercept APG101; CAN008	TNF Receptor	Inflammation/Immunology Cancer
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein (hIgG1) targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .

HY-115630

cRIPGBM chloride	RIP kinase Caspase Apoptosis	Cancer
cRIPGBM chloride, an orally active, proapoptotic derivative. cRIPGBM can be generated from glioblastoma multiforme (GBM) cancer stem cells (CSCs). cRIPGBM(chloride) targets to receptor-interacting protein kinase 2 (RIPK2) to induce caspase 1-dependent apoptosis. cRIPGBM(chloride) suppresses the formation of RIPK2/TAK1 (prosurvival complex), and increases the formation of RIPK2/caspase 1 (proapoptotic complex). cRIPGBM(chloride) exerts potent anti-tumor activity in vivo in animal models .

HY-160972

MM0299	LXR	Neurological Disease Cancer
MM0299 is a selective lanosterol synthase (LSS) inhibitor with an IC₅₀ value of 2.22 μM. MM0299 depletes intracellular cholesterol and acts as a growth inhibitor for glioma stem-like cells. MM0299 exhibits anti-glioblastoma activity. MM0299 is applicable to research related to glioblastoma .

HY-124813

PDZ1i 113B7	FAK EGFR MMP NF-κB SDCBP	Cancer
PDZ1i (113B7) is a inhibitor of MDA-9/Syntenin, with selective binding to the PDZ1 domain. PDZ1i inhibits radiation-induced invasion of glioblastoma (GBM) cells, radiosensitizes GBM cells, and impairs GBM-related signaling pathways (including Src/EphA2, EGFRvIII/FAK, and NF-κB). PDZ1i reduces radiation-induced secretion of invasion-related proteases (MMP-2, MMP-9, ADAM9). PDZ1i shows anti-tumor effects in nude mice bearing intracranial U1242-luc xenografts or GBM xenografts. PDZ1i can be used for the study of glioblastoma (GBM), breast cancer and prostate cancer .

HY-162153

CYY292	FGFR	Cancer
CYY292 is an FGFR1 inhibitor that specifically targets the FGFR1/AKT/Snail pathway in GBM cells. CYY292 dose-dependently inhibits cancer cell proliferation, epithelial-mesenchymal transition, stemness, invasion, and migration in vitro .

HY-175207

CHI3L1-IN-3	Glycosidase	Cancer
CHI3L1-IN-3 is a CHI3L1 inhibitor. CHI3L1-IN-3 binds to CHI3L1 with K_ds of 13.76 μM and 13.5 μM in MST and SPR assays, respectively. CHI3L1-IN-3 demonstrates extended plasma half-lives and microsomal stability, along with reduced intrinsic clearance. CHI3L1-IN-3 induces dose-dependent cytotoxicity, reduces spheroid mass and inhibits migration in a 3D multicellular glioblastoma (GBM) spheroid model. CHI3L1-IN-3 can be used for the study of GBM .

HY-117357

SI-113	SGK	Cancer
SI-113 is a SGK1 inhibitor, with an IC₅₀ of 600 nM. SI113 induces autophagy .

HY-N5025

Bullatine A	P2X Receptor Apoptosis ERK p38 MAPK c-Myc NF-κB Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology Cancer
Bullatine A, a diterpenoid alkaloid, is a potent P2X7 antagonist. Bullatine A possesses anti-rheumatic, anti-inflammatory and anti-nociceptive effects. Bullatine A inhibits ATP-induced BV-2 cell death/apoptosis and P2X receptor-mediated inflammatory responses. Bullatine A suppresses glioma cell growth by targeting SIRT6. Bullatine A specifically attenuates pain hypersensitivity in rats. Bullatine A attenuates LPS (HY-D1056)-induced systemic inflammatory response by inhibiting the ROS/JNK/NF-κB pathway in mice. Bullatine A improves despair behavior in Chronic chronic social defeat stress (CSDS) mice. Bullatine A can be used for the study of inflammation, glioblastoma (GBM) and depression .

HY-112293

GW2974	EGFR	Cancer
GW2974 is a potent dual inhibitor of EGFR and HER2 with IC₅₀ value of 0.007 μM and 0.016 μM, respectively. GW2974 demonstrates in vitro inhibition of the EGFR and HER2 and inhibits the growth of tumor cell. GW2974 can be used for glioblastoma multiforme (GBM) disease research .

HY-155888

IV-255	Epigenetic Reader Domain	Cancer
IV-255 is a selective small molecule inhibitor of the BRG1 bromodomain. IV-255 increases the extent of DNA damage induced by Temozolomide (HY-17364) and Bleomycin (HY-108345). IV-255 inhibits the invasiveness of GBM cells. IV-255 enhances Temozolomide-induced cell death and the apoptosis-inducing activity of Temozolomide .

HY-148833

MDM2-p53-IN-16	MDM-2/p53	Cancer
MDM2-p53-IN-16 is a MDM2-p53 complex inhibitor with an IC₅₀ value of 4.3 nM to dissociate human p53/MDM2 complex. MDM2-p53-IN-16 reactivates p53, and induces Glioblastoma Multiforme (GBM) cell apoptosis and cell-cycle arrest. MDM2-p53-IN-16 can be used for the cancer research .

HY-173066

NU227326	PROTACs Indoleamine 2,3-Dioxygenase (IDO)	Cancer
NU227326 is a blood-brain barrier penetrant IDO1 PROTAC degrader, with a DC₅₀ of 4.5 nM in HiBiT degradation assays. NU227326 degrades IDO1 in U87 and GBM43 cells, with DC₅₀ values of 7.1 nM and 11.8 nM, respectively (WB assays). NU227326 is applicable to research related to glioblastoma, prostate cancer, triple-negative breast cancer, pancreatic cancer, and ovarian cancer .

HY-122910

RIPGBM	Apoptosis	Cancer
RIPGBM is a selective inducer of apoptosis in glioblastoma multiforme (GBM) cancer stem cells (CSCs) with an EC₅₀ of ≤500 nM .

HY-168708

AH2-14c	Histone Demethylase Apoptosis	Cancer
AH2-14c is an inhibitor for DNA demethylase ALKBH2. AH2-14c inhibits the cell viability (IC₅₀ is 4.56 µM) and migration of GBM U87. AH2-14c regulates the expression of apoptosis-related genes, and induces apoptosis in GBM U87 cell .

HY-N3001

Isolinderalactone 1 Publications Verification	STAT VEGFR Bcl-2 Family Survivin IAP NF-κB Apoptosis Caspase	Neurological Disease Inflammation/Immunology Cancer
Isolinderalactone is a sesquiterpene that exhibits anti-cancer, anti-inflammatory, and neuroprotective effects. Isolinderalactone inhibits VEGF expression and tyrosine phosphorylation of VEGFR2. Isolinderalactone decreases viability and induces apoptosis in U-87 glioblastoma (GBM) cells and colorectal cancer (CRC) cells. Isolinderalactone induces G2/M phase cell cycle arrest, ROS generation, pJNK/p38 MAPK activation, in colorectal cancer (CRC) cells. Isolinderalactone blocks LPS (HY-D1056)-induced NF-κB activation while activating Nrf2-HMOX1 signaling in RAW264.7 macrophages. Isolinderalactone improves cognitive dysfunction in APP/PS1 mice. Isolinderalactone can be used for the study of Glioblastoma multiforme (GBM), colorectal cancer, Alzheimer’s disease and acute lung injury .

HY-111187

KX2-361 KX-02	Src Microtubule/Tubulin Apoptosis	Cancer
KX2-361 (KX-02) is a Src-kinase and tubulin polymerization inhibitor. KX2-361 shows good oral bioavailability and readily crosses the BBB in mice. KX2-361 shows anti-tumor activity and induces apoptosis of Glioblastoma (GBM) cell .

HY-14942

Berubicin RTA 744 free base; WP 744 free base; WP 769	NF-κB Apoptosis Caspase Drug Derivative	Neurological Disease Cancer
Berubicin (RTA 744 free base) is a Doxorubicin (HY-15142A) analog that can cross the blood-brain barrier. Berubicin inhibits P-gp and MRP1-mediated efflux and suppresses glioblastoma multiforme (GBM). Berubicin exerts toxic effects on leukemia cells by activating nuclear factor κB (NF-κB) and induces apoptosis in neuroblastoma cells. Berubicin can be used in the study of tumors related to the nervous system .

HY-17595R

Mebendazole (Standard)	Reference Standards Parasite Apoptosis Microtubule/Tubulin	Infection Cancer
Mebendazole (Standard) is the analytical standard of Mebendazole. This product is intended for research and analytical applications. Mebendazole is a highly effective, broad-spectrum antihelmintic against nematode infestations. Mebendazole also exhibits inhibitory effect against glioblastoma multiforme (GBM), inhibits Hedgehog pathway and tubulin polymerization. Mebendazole is orally active and can cross CNS penetration .

HY-125964

LLP-3	Survivin	Cancer
LLP-3 is a potent Survivin inhibitor that disrupts the Survivin-Ran interaction in cancer cells. LLP-3 can be used in the research of Glioblastoma multiforme (GBM) .

HY-162384

EPIC-0628	Histone Methyltransferase	Cancer
EPIC-0628 is an inhibitor of the HOTAIR-EZH2 interaction and promotes ATF3 expression. The long noncoding RNA HOTAIR has been found to regulate glioblastoma (GBM) progression and mediate DNA damage repair (DDR) by interacting with the catalytic subunit EZH2 of PRC2. EPIC-0628 also inhibits the ATF3-p38-E2F1 DDR pathway to inhibit the HR pathway and upregulates CDKN1A (p21) expression, causing cell cycle arrest. EPIC-0628 also synergizes with Temozolomide (TMZ) (HY-17364) to enhance its in vivo potency .

HY-144720

BRG1-IN-1	SWI/SNF Complex	Cancer
BRG1-IN-1 (Compound 11d) is a potent inhibitor of SMARCA4/BRG1. BRG1-IN-1 shows better efficacy than PFI-3 in sensitizing GBM cells to the antiproliferative and cell death inducing effects of Temozolomide in vitro. BRG1-IN-1 enhances the inhibitor effect of Temozolomide on the growth of subcutaneous GBM tumors .

HY-P99715

Losatuxizumab	EGFR	Cancer
Losatuxizumab is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC₅₀s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFR ^C271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers .

HY-174212

MXC-017	Apoptosis	Cancer
MXC-017 is a blood-brain barrier (BBB)-penetrant apoptosis inducer that directly targets Vimentin (VIM). MXC-017 prevents radiation-induced glioma stem cell (GSC) formation, while promoting G0/G1 cell cycle arrest and apoptosis. MXC-017 exhibits minimal off-target effects and shows no significant cytotoxicity. MXC-017 significantly prolongs median survival when used in combination with radiation therapy in glioblastoma (GBM) mouse models.

HY-125466

cRIPGBM	RIP kinase Apoptosis Caspase	Cancer
cRIPGBM, a proapoptotic derivative of RIPGBM, a cell type-selective inducer of apoptosis in GBM cancer stem cells (CSCs) by binding to receptor-interacting protein kinase 2 (RIPK2), with an EC₅₀ of 68 nM in GBM-1 cells .

HY-13610B

N1,N11-Diethylnorspermine hydrobromide	Caspase	Cancer
N1,N11-Diethylnorspermine hydrobromide is a potent anticancer agent. N1,N11-Diethylnorspermine hydrobromide is a spermine analog that activates polyamine catabolism. N1,N11-Diethylnorspermine hydrobromide induces the release of cytochrome c from mitochondria, resulting in activation of caspase 3. N1,N11-Diethylnorspermine hydrobromide kills glioblastoma multiforme (GBM) cells through induction of SSAT (spermidine/spermine N1-acetyltransferase) coupled with H2O2 production .

HY-W278944

Antiproliferative agent-15	Drug Derivative	Cancer
Antiproliferative agent-15 is an thienopyrimidine derivated anticancer agent. Antiproliferative agent-15 shows antiproliferative activity against human colon (HCT116 and HCT15) and brain (LN-229 and GBM-10) cancer cell lines .

HY-13610

N1,N11-Diethylnorspermine Diethylnorspermine; BENSPM; DENSPM; BE-333	Caspase mTOR	Cancer
N1,N11-Diethylnorspermine is a synthetic analog of the naturally occurring polyamine spermine, can induce polyamine depletion and inhibit tumor cell growth. N1,N11-Diethylnorspermine activates polyamine catabolism and downregulates mTOR protein. N1,N11-Diethylnorspermine induces the release of cytochrome c from mitochondria, resulting in activation of caspase 3. N1,N11-Diethylnorspermine tetrahydrochloride kills glioblastoma multiforme (GBM) through induction of SSAT (spermidine/spermine N1-acetyltransferase) coupled with H₂O₂ production .

HY-175299

Hedgehog IN-11	Hedgehog Apoptosis DNA Methyltransferase	Cancer
Hedgehog IN-11 is an orally active Hedgehog inhibitor. Hedgehog IN-11 downregulates the expression of O6-methylguanine-DNA methyltransferase (MGMT) to impair the Temozolomide (TMZ) (HY-17364) resistance by inhibiting the Hedgehog pathway. Hedgehog IN-11 shows improved inhibition of cell migration and invasion, and induced cell apoptosis in TMZ-resistant GBM cell lines. Hedgehog IN-11 is predicted by computer simulation to have good blood-brain barrier penetration. Hedgehog IN-11 can be used for the study of glioblastoma (GBM) .

HY-114413

YZ129	HSP Apoptosis	Cancer
YZ129 is an inhibitor of the HSP90-calcineurin-NFAT pathway against glioblastoma, directly binding to heat shock protein 90 (HSP90) with an IC₅₀ of 820 nM on NFAT nuclear translocation. YZ129-induced GBM cell-cycle arrest at the G2/M phase promotes apoptosis and inhibited tumor cell proliferation and migration .

HY-103407

PD 168568	Dopamine Receptor	Neurological Disease Cancer
PD 168568 is a orally active and potent dopamine receptor D₄ (DRD₄) antagonist. PD 168568 contains an isoindolinone and is selective for the D₄ receptor versus D₂ and D₃, with K_i values of 8.8, 1842, and 2682 nM, respectively. PD 168568 can be used for glioblastoma (GBM) research .

HY-178969

GZD-257	FAK Pyk2 Apoptosis	Neurological Disease Cancer
GZD-257 is a brain-penetrant, ATP-competitive FAK inhibitor (IC₅₀ = 14.3 nM), performing 4.77-fold selectivity with FAK to Pyk2 (IC₅₀ = 68.2 nM). GZD-257 can significantly induce apoptosis of U118MG cells and arrest the cell cycle at the G2/M phase. GZD-257 can be used for the study of Glioblastoma (GBM) .

HY-178499

CDK9-IN-44	CDK c-Myc Bcl-2 Family	Neurological Disease Cancer
CDK9-IN-44 (Compound 7) is a selective CDK9 inhibitor (IC₅₀=7.6 μM). CDK9-IN-44 inhibits CDK9/cyclin T1 kinase activity, blocking transcriptional elongation, reducing the expression of pro-cancer proteins (such as MCL1, c-MYC), and inducing tumor cell apoptosis. CDK9-IN-44 is promising for research of glioblastoma (GBM) and central nervous system (CNS) disorders .

HY-155580

MAO A/HSP90-IN-2	Monoamine Oxidase HSP	Cancer
MAO A/HSP90-IN-2 (compound 4-C) is a dual inhibitor of HSP90and MAO A with the IC₅₀ values of 0.016 and 4.58 μM, respectively. MAO A/HSP90-IN-2 increases HSP70 expression and reduces HER2 and phospho-Akt expression, and decreases IFN-γ induced PD-L1 expression in GL26 cells. MAO A/HSP90-IN-2 inhibits the growth of Temozolomide (HY-17364) -sensitive and -resistant GBM cells, colon cancer, leukemia, non-small cell lung and other cancers, and has potential to inhibit tumor immune escape ^[1].

HY-155532

10m/ZS44	Apoptosis	Cancer
10m/ZS44 is a blood-brain barrier-permeable Glioblastoma (GBM) inhibitor. 10m/ZS44 significantly inhibits GBM tumor growth in a mouse xenograft model. 10m/ZS44 also activates the SIRT1/p53-mediated apoptosis pathway, thereby inhibiting the proliferation of U251 cells .

HY-144438

Aurora/LIM kinase-IN-1	Aurora Kinase LIM Kinase (LIMK)	Cancer
Aurora/LIM kinase-IN-1 (Compound F114) is a potent and dual inhibitor of aurora and lim kinase. Aurora kinases and lim kinases are involved in neoplastic cell division and cell motility, respectively. Aurora/LIM kinase-IN-1 inhibits GBM proliferation and invasion. Aurora/LIM kinase-IN-1 is a promising new scaffold for dual aurora/lim kinase inhibitors that may be used in future agent development efforts for GBM, and potentially other cancers .

HY-172586

GSK-3α/β-IN-1	GSK-3 PKA	Neurological Disease Cancer
GSK-3α/β-IN-1 is GSK-3α/β inhibitor with IC₅₀s of 0.265 μM and 0.255 μM for GSK-3α and GSK-3β, respectively. GSK-3α/β-IN-1 also inhibits PKA with an IC₅₀ of 0.188 μM. GSK-3α/β-IN-1 potently inhibits cell viability of three Glioblastoma (GBM) cell lines (IC₅₀: 3-6 μM, 72 h) with no toxicity to human astrocytes and good metabolic stability. GSK-3α/β-IN-1 has potential CNS activity in all-human blood-brain barrier (BBB) model of GBM .

HY-155889

IV-275	Epigenetic Reader Domain	Cancer
IV-275 is an inhibitor of both BRG1 and BRM bromodomains. IV-275 increases the extent of DNA damage induced by Temozolomide (HY-17364) and Bleomycin (HY-108345). IV-275 inhibits the invasiveness of GBM cells. IV-275 enhances Temozolomide-induced cell death and the apoptosis-inducing activity of Temozolomide .

HY-161946

GBM CSCs-IN-1	DNA/RNA Synthesis Apoptosis	Cancer
GBM CSCs-IN-1 (Compound (−)-20), a derivative of rocaglate, is a potent inhibitor of glioblastoma stem cells (GBM CSCs) with an EC₅₀ of 45 nM, functioning by targeting the RNA helicase DDX3. Furthermore, GBM CSCs-IN-1 is also capable of inducing apoptosis .

HY-N9341

Norswertianin	Autophagy	Cancer
Norswertianin, a xanthone compound, serves as a powerful anti-glioma compound. Norswertianin induces GBM cells differentiation through oxidative stress and Akt/mTOR dependent autophagy .

HY-147789

FPDT	Akt	Neurological Disease Cancer
FPDT is an anti-glioblastoma agent. FPDT displays the IC₅₀ value of 45–68 μM for GBM cells and >100 μM for astrocytes. Anti-glioblastoma activity of FPDT is linked to downregulation of the AKT pathway .

HY-161256

Tubulin inhibitor 41	Microtubule/Tubulin Apoptosis	Cancer
Tubulin inhibitor 41 (Compd D19), a promising anti-GBM (glioblastoma) lead compound and tublin inhibitor with BBB permeability, induces G2/M phase arrest, resulted in cell apoptosis and inhibits the migration of U87 cells .

Cat. No.	Product Name	Target	Research Area	Image